AUC of Bempegaldesleukin [Pharmacokinetic Parameter].;Cmax of Bempegaldesleukin [Pharmacokinetic Parameter].;Number of Participants Experiencing Dose-Limiting Toxicities (DLTs);Number of Participants With Treatment-Emergent Adverse Events [Safety and Tolerability];Percent Change From Baseline for Absolute Lymphocyte Count (ALC) by Dose/Arm.;Tmax of Bempegaldesleukin [Pharmacokinetic Parameter].

AUC of Bempegaldesleukin [Pharmacokinetic Parameter].;Cmax of Bempegaldesleukin [Pharmacokinetic Parameter].;Number of Participants Experiencing Dose-Limiting Toxicities (DLTs);Number of Participants With Treatment-Emergent Adverse Events [Safety and Tolerability];Percent Change From Baseline for Absolute Lymphocyte Count (ALC) by Dose/Arm.;Tmax of Bempegaldesleukin [Pharmacokinetic Parameter].

Cmax of BEMPEG /SOC (PK).;AUC of BEMPEG/standard of care (SOC) (PK).;Tmax of BEMPEG /SOC (PK).;Incidence of adverse events.;Incidence of treatment emergent adverse events (TEAEs).;Incidence of serious adverse events (SAEs).;Incidence of dose limiting toxicities (DLT) for BEMPEG.;Presence and levels of anti-drug antibodies directed to BEMPEG.;Fold change from baseline in absolute lymphocyte count by Central Laboratory.

Cmax of BEMPEG /SOC (PK).;AUC of BEMPEG/standard of care (SOC) (PK).;Tmax of BEMPEG /SOC (PK).;Incidence of adverse events.;Incidence of treatment emergent adverse events (TEAEs).;Incidence of serious adverse events (SAEs).;Incidence of dose limiting toxicities (DLT) for BEMPEG.;Presence and levels of anti-drug antibodies directed to BEMPEG.;Fold change from baseline in absolute lymphocyte count by Central Laboratory.